Ligand Pharmaceuticals Incorporated · NASDAQ:LGND

Reardon Andrew sold 5,000 Ligand Pharmaceuticals Incorporated shares (Form 4)

Traded Jun 30 to Jul 1, 2026 · Filed Jul 6, 2026

From Jun 30 to Jul 1, 2026, Reardon Andrew (CLO & Secretary) sold 5,000 Ligand Pharmaceuticals Incorporated shares at an average US$313.28 for US$1.57M under a trading plan, leaving 41,514 shares. Filed Jul 6, 2026 (Form 4).

Sold
5,000 shares
Price
US$313.28 average (US$308.99 to US$317.15)
Value
US$1.57M
Holding after
41,514 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CLO & Secretary

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 30, 2026Common StockOther132US$160.7141,514Direct
Jul 1, 2026Common StockOption exercise5,000US$52.2746,514Direct
Jul 1, 2026Common StockSale396US$308.9946,118Direct
Jul 1, 2026Common StockSale104US$310.2046,014Direct
Jul 1, 2026Common StockSale1,119US$311.7244,895Direct
Jul 1, 2026Common StockSale1,081US$312.2843,814Direct
Jul 1, 2026Common StockSale700US$313.4643,114Direct
Jul 1, 2026Common StockSale100US$314.5843,014Direct
Jul 1, 2026Common StockSale900US$315.7842,114Direct
Jul 1, 2026Common StockSale600US$317.1541,514Direct

Source

View original at SEC

Related